Core Scientific, Inc. current report, 04 July 2023

Full document

Core Scientific, Inc. — Form 8-K Summary

Business Context and Reporting Period

Core Scientific filed this Current Report on July 6, 2023, reporting events occurring on July 4, 2023. The company and certain affiliates remain debtors-in-possession in Chapter 11 proceedings initiated on December 21, 2022, in the U.S. Bankruptcy Court for the Southern District of Texas.

Material Financing and Liquidity Update

  • On July 4, 2023, the debtors entered into a First Amendment to their Replacement Debtor-in-Possession Credit Agreement with B. Riley Commercial Capital, LLC, as administrative agent, and the participating DIP lenders.
  • The amendment permits certain transfers or payments related to settlements of specified third-party claims.
  • The amendment reduces the Excess Cash threshold to $40.0 million plus an amount, not less than zero, equal to $5.0 million less applicable payments made after June 30, 2023, on prepetition claims, liens, or cure costs.
  • The company anticipated making an additional $5.0 million mandatory prepayment under the Replacement DIP Credit Agreement on or before July 10, 2023.

Changes Versus the Prior Comparable Period

This filing does not provide comparative operating or financial results. The material change disclosed is the amendment to the DIP financing arrangements, including the lower Excess Cash threshold, permitted claim-settlement payments, and anticipated additional mandatory prepayment.

Guidance, Outlook, Risks, and Unusual Items

  • The company continues to operate under Chapter 11 supervision and in accordance with the Bankruptcy Code and Bankruptcy Court orders.
  • Liquidity remains subject to the terms of the Replacement DIP Credit Agreement, including mandatory prepayment requirements and cash thresholds.
  • The filing does not provide revenue, profit, cash flow, margin, total debt, cash balance, or other operating guidance.
  • The bankruptcy proceedings, third-party claim settlements, prepetition claims, liens, cure costs, and DIP financing obligations are significant contingencies and risks.

Important Facts for Investors to Verify

  • Whether the anticipated $5.0 million mandatory DIP prepayment was made by July 10, 2023.
  • The final Excess Cash threshold after accounting for post-June 30, 2023 payments on prepetition claims, liens, or cure costs.
  • The complete terms of the First Amendment filed as Exhibit 10.1.
  • The status of the Chapter 11 cases, including any subsequent restructuring plan, financing amendments, or Bankruptcy Court orders.
  • The company’s current cash position, DIP borrowings, operating cash flow, and remaining liquidity, which are not provided in this filing.